Inhibition of pancreatic lipase activity is one of the most effective methods for the treatment of obesity and obesity-related metabolic disorders, such as atherosclerosis and hyperlipidemia. Here, PNLIP is linked to obesity due to melanocortin 4 receptor deficiency.